patent.fyi
Applications  /  US 2026/0355178
United States Patent Application Publication

US 2026/0355178 A1

Published
Nov 12, 2026
Filed
Sep 29, 2023
Earliest date on the face
Oct 21, 2022
Classification
A61K 31/4709
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Lamin B1 attachment site substitution

What ifWhat if a targeted DNA edit substitutes serine for the farnesyl attachment site on lamin B1?
Claim language“a farnesyltransferase inhibitor”

A guide RNA and a DNA repair template direct a codon change at the cysteine in the C-terminal farnesylation motif. Newly synthesized lamin B1 carries serine at that position and lacks the cysteine thiol that accepts the farnesyl group.

1.1Farnesyl donor depletion

What ifWhat if an upstream metabolic intervention limits the supply of farnesyl diphosphate?
Claim language“a farnesyltransferase inhibitor”

An inhibitor of hydroxymethylglutaryl coenzyme A reductase reduces mevalonate production and lowers the supply of downstream isoprenoid intermediates. When farnesyl diphosphate becomes limiting, farnesyltransferase has less donor available for modifying newly synthesized lamin B1.

1.1Farnesyltransferase subunit depletion

What ifWhat if the cell produces less farnesyltransferase by degrading messenger RNA for its beta subunit?
Claim language“a farnesyltransferase inhibitor”

A small interfering RNA directs the RNA-induced silencing complex to the transcript encoding the farnesyltransferase beta subunit. As existing enzyme turns over, fewer active enzyme complexes are available to modify newly synthesized lamin B1.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Cellular screening in pharmaceutical process development

A pharmaceutical process development laboratory seeds donor-derived dermal fibroblasts into multiwell plates and exposes them to test lots of a farnesyltransferase inhibitor. Each plate includes vehicle controls and a retained reference lot tested at the same concentrations. Targeted mass spectrometry measures the fraction of lamin B1 carrying a farnesyl group at its C terminus, and the laboratory compares this fraction across lots.

Component substitution

Peptidomimetic inhibitor with a thiol group

A thiol-bearing CVFM peptidomimetic with a reduced amide linkage replaces the heterocyclic farnesyltransferase inhibitor. Its cysteine-like thiol coordinates zinc in the enzyme active site, and its terminal residues occupy the peptide substrate binding region. The compound is added to cultured donor-derived fibroblasts, and targeted mass spectrometry measures the farnesylated fraction of lamin B1 relative to a vehicle control.

Parameter or scale variation

Timed dose matrix in microplates

Three 96-well plates receive donor-derived fibroblasts at 5,000 cells per well, with one plate assigned to each of three harvest times at 24, 48, and 72 hours. Each plate carries triplicate wells at eight concentrations in a threefold dilution series, along with vehicle controls. At each harvest, replicate lysates are pooled by concentration and analyzed for farnesylated and total lamin B1.

Pulse dosing with recovery sampling

Parallel cultures of donor-derived fibroblasts receive either a 6-hour inhibitor pulse or continuous inhibitor exposure at the same concentration. At the end of the pulse, two exchanges with inhibitor-free medium clear the dosing solution from the pulse cultures, and matched control cultures undergo the same exchanges. Replicate cultures are harvested at 0, 24, and 48 hours after the exchanges to measure the recovery of the farnesylated lamin B1 fraction.

Combination with existing systems

Inhibitor delivery through a perfused chip

Donor-derived dermal fibroblasts grow on the floor of parallel microfluidic culture channels connected to a syringe pump. One channel receives medium containing a farnesyltransferase inhibitor, and a matched channel receives medium containing the same vehicle concentration. After perfusion, the cells are lysed in the channels and the collected lysates are analyzed for the farnesylated fraction of lamin B1.

Automated or data-driven variant

Software fitted cellular dose response

A robotic liquid handler transfers serial dilutions of a farnesyltransferase inhibitor to wells containing donor-derived fibroblasts. Software associates each well with its dose, viable cell count, and targeted mass spectrometry measurements of farnesylated and total lamin B1. The software fits a four-parameter dose response to the farnesylated fraction and reports the midpoint when the measured responses span it.

Specific version of a part

Cysteine containing peptidomimetic inhibitor

A cysteine-containing peptidomimetic occupies the enzyme’s recognition site for C-terminal protein substrates. The compound is added to the culture medium in a concentration series, and the reduction in lamin B1 farnesylation defines the effective concentration under those culture conditions.

Quinolinone small molecule inhibitor

A quinolinone-based small molecule binds in the farnesyltransferase substrate pocket and reduces transfer of farnesyl groups to lamin B1. A concentration series in culture medium and a matched vehicle control establish the concentration that reduces the fraction of farnesylated lamin B1.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 10,980,793 B2
Published
Apr 20, 2021
Filed
Aug 14, 2019
Class
A61K 31/4709
Document BUS 2022/0305001 A1
Published
Sep 29, 2022
Filed
May 1, 2020
Class
A61K 31/4709
Claim 1
Document A
Document B
1.1administering to the cell an effective amount of a farnesyltransferase inhibitor (FTI).
Provided herein are methods to treat CXCL12-expressing cancer in a subject including administering a therapeutically effective amount of an FTI to the subject having a CXCL12-expressing cancer.
A · US 10,980,793 B2 · ¶ 4
Provided herein are methods to treat FLT3LG-expressing AML in a subject that include administering a therapeutically effective amount of an FTI to the subject.
B · US 2022/0305001 A1 · ¶ 3

An empty cell means only that no passage was reproduced there.

Statements in these documents
Therefore, methods to predict the responsiveness of a subject having cancer to an FTI treatment, or methods to select cancer patients for an FTI treatment, represent unmet needs.
A · US 10,980,793 B2 · ¶ 3
Provided herein are also methods to predict the responsiveness of a subject having cancer for an FTI treatment, methods to select a cancer patient for an FTI treatment, methods to stratify cancer patients for an FTI treatment, and methods to increase the responsiveness of a cancer patient population for an FTI treatment.
A · US 10,980,793 B2 · ¶ 4
Therefore, methods to predict the responsiveness of a subject having cancer to an FTI treatment, or methods to select cancer patients for an FTI treatment, represent unmet needs.
B · US 2022/0305001 A1 · ¶ 2
Provided herein are also methods to predict the responsiveness of a subject having AML to an FTI treatment, methods to select an AML patient for an FTI treatment, methods to stratify AML patients for an FTI treatment, and methods to increase the responsiveness of an AML patient population for an FTI treatment.
B · US 2022/0305001 A1 · ¶ 3
Cite aspatent.fyi, US 2026/0355178 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355178/, SHA-256 0a14fab1ce3106917586b926e53208c834d7a22ff868ed87c4af69337e636631
First published
Permanent addresshttps://patent.fyi/US20260355178/
Content fingerprint (SHA-256)0a14fab1ce3106917586b926e53208c834d7a22ff868ed87c4af69337e636631
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi